GlassScriptPhysician profile
Devin B Farr
NPI 1750643896
$2,205.33
in general payments reported to CMS, 2019-2025
26 companies · $457 in 2025
The $457 reported for 2025 was more than what 75% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $346 · 2020: $139 · 2021: $144 · 2022: $236 · 2023: $368 · 2024: $515 · 2025: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,287 · Honoraria: $53.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,286.59 |
| Honoraria | $53.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $329.93 | 2022-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $230.67 | 2019-2025 | Amo Phaco Needle, Veritas Vision System |
| Novartis Pharmaceuticals Corporation | $227.29 | 2019-2023 | |
| Alcon Vision LLC | $199.93 | 2019-2025 | Precision7, Tryptyr, Clareon Panoptix Pro |
| Bausch & Lomb Americas INC. | $131.89 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Sun Pharmaceutical Industries INC. | $131.42 | 2019-2025 | |
| Glaukos Corporation | $127.56 | 2022-2025 | Idosetr, Istent Infinite Trabecular Micro-Bypass System Model Is3, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3 |
| Allergan, INC. | $105.10 | 2019-2021 | |
| Shire North American Group INC | $84.30 | 2019 | |
| Rxsight INC | $76.57 | 2023-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Johnson & Johnson Vision Care, INC. | $74.24 | 2019-2025 | Acuvue |
| Coopervision INC. | $69.19 | 2023 | Myday Contact Lens, Biofinity Contact Lens |
| Regeneron Healthcare Solutions, INC. | $66.07 | 2022-2024 | Eylea, Eylea Hd |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $57.78 | 2019 | |
| Oyster Point Pharma, INC. | $46.40 | 2022-2024 | Tyrvaya |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $46.13 | 2022-2024 | |
| Astellas Pharma US INC | $38.69 | 2025 | Izervay |
| Apellis Pharmaceuticals, INC. | $36.01 | 2025 | Syfovre |
| Tarsus Pharmaceuticals, INC. | $23.38 | 2025 | Xdemvy |
| Amgen INC. | $23.19 | 2025 | Tepezza |
| Harrow Eye, LLC | $17.28 | 2025 | Iheezo |
| Thea Pharma INC. | $15.84 | 2025 | Iyuzeh |
| Dompe US, INC. | $12.01 | 2021 | |
| Sight Sciences, INC. | $11.75 | 2021 | |
| Horizon Therapeutics Plc | $11.62 | 2021 | |
| Genentech, INC. | $11.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devin Farr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.